KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a further decision by the Singapore International Commercial Court (the "Court") to maintain the temporary injunction ...

The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these ...

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt:PF0) a premier artificial intelligence (AI) company transforming clinical trials today announced ...

The announcement of this study could positively influence AstraZeneca’s stock performance and investor sentiment, given the potential for BGF MDI to become a significant treatment option for COPD.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Parexel, one of the world's largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointment of Jeff Bernstein, ...

The latest international Parexel International Corporation news and views from Reuters - one of the world's largest news agencies ...

Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of phase I to IV clinical development services, and Palantir Technologies Inc., a leading builder of ...

Parexel, a contract research organization (CRO), and Partex, a data-to-drugs pharma platform, have inked a deal aiming to leverage artificial intelligence (AI)-powered solutions to accelerate drug ...

Parexel-Partex collab to use AI-driven solutions to accelerate drug discovery & de-risk biopharmaceutical portfolios. Combining Parexel's clinical dev. expertise & Partex's big data & AI ...

The collaboration between Parexel and Partex is designed to leverage artificial intelligence-powered solutions to accelerate drug discovery and development.